Answers are grounded in this paper and cite their sources.
This review discusses the current laboratory, pharmacological, and clinical knowledge regarding the use of anticoagulants like heparin, warfarin, and low molecular weight heparin for venous thromboembolism.
The anticoagulant agents heparin and warfarin were introduced before the era of randomised clinical trials. As a result, the indications, dosages and monitoring techniques of these drugs have undergone re-evaluation in multiple clinical trials in the past years. Low molecular weight heparin has been developed, which has led to new approaches in anticoagulant management. Current levels of laboratory, pharmacology and clinical knowledge in the treatment of venous thromboembolism are discussed.
No takes yet. Share an insight, caveat, or question.
Cheng‐Hock Toh (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: